全文获取类型
收费全文 | 41493篇 |
免费 | 2869篇 |
国内免费 | 161篇 |
专业分类
耳鼻咽喉 | 500篇 |
儿科学 | 1347篇 |
妇产科学 | 553篇 |
基础医学 | 4991篇 |
口腔科学 | 526篇 |
临床医学 | 4271篇 |
内科学 | 9215篇 |
皮肤病学 | 702篇 |
神经病学 | 3937篇 |
特种医学 | 1669篇 |
外科学 | 7222篇 |
综合类 | 359篇 |
一般理论 | 81篇 |
预防医学 | 3127篇 |
眼科学 | 1155篇 |
药学 | 2148篇 |
中国医学 | 39篇 |
肿瘤学 | 2681篇 |
出版年
2024年 | 32篇 |
2023年 | 400篇 |
2022年 | 685篇 |
2021年 | 1563篇 |
2020年 | 772篇 |
2019年 | 1287篇 |
2018年 | 1559篇 |
2017年 | 1066篇 |
2016年 | 1170篇 |
2015年 | 1254篇 |
2014年 | 1752篇 |
2013年 | 2066篇 |
2012年 | 3476篇 |
2011年 | 3468篇 |
2010年 | 1889篇 |
2009年 | 1680篇 |
2008年 | 2803篇 |
2007年 | 2741篇 |
2006年 | 2645篇 |
2005年 | 2500篇 |
2004年 | 2442篇 |
2003年 | 2044篇 |
2002年 | 1884篇 |
2001年 | 239篇 |
2000年 | 170篇 |
1999年 | 240篇 |
1998年 | 357篇 |
1997年 | 312篇 |
1996年 | 232篇 |
1995年 | 220篇 |
1994年 | 166篇 |
1993年 | 162篇 |
1992年 | 110篇 |
1991年 | 108篇 |
1990年 | 80篇 |
1989年 | 70篇 |
1988年 | 50篇 |
1987年 | 61篇 |
1986年 | 58篇 |
1985年 | 59篇 |
1984年 | 74篇 |
1983年 | 83篇 |
1982年 | 102篇 |
1981年 | 76篇 |
1980年 | 52篇 |
1979年 | 26篇 |
1978年 | 32篇 |
1977年 | 33篇 |
1976年 | 20篇 |
1973年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
Cytomegalovirus Disease in High-Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis 总被引:10,自引:0,他引:10
Enver Akalin Vinita Sehgal Scott Ames Sabera Hossain Lisa Daly Murphy Barbara Jonathan S. Bromberg 《American journal of transplantation》2003,3(6):731-735
The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6-18 months). The overall incidence of CMV disease at 1-year post-transplant was 14% (4% tissue-invasive, 10% noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2-28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient - CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17%, respectively). Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High-risk individuals might require higher doses or longer duration of valganciclovir treatment. 相似文献
72.
73.
74.
Solish Nowell MD Benohanian Antranik MD Jonathan W. Kowalski PharmD MS on Behalf of the Canadian Dermatology Study Group on Health-Related Quality of Life in Primary Axillary Hyperhidrosis 《Dermatologic surgery》2005,31(4):405-413
BACKGROUND: Patients with primary axillary hyperhidrosis experience substantial functional impairment and reduced health-related quality of life (HRQOL). Few studies have comprehensively evaluated the effects of botulinum toxin type A (BoNT-A) on these symptoms. OBJECTIVE: To prospectively assess the effects of BoNT-A on functional impairment associated with primary axillary hyperhidrosis. METHODS: Patients treated with BoNT-A 50 U per axilla at baseline were assessed 4 and 12 weeks later. Outcome measures included functional impairment as assessed by the Hyperhidrosis Disease Severity Scale and the Hyperhidrosis Impact Questionnaire and dermatology-specific HRQOL as assessed by the Dermatology Life Quality Index. RESULTS: At weeks 4 and 12 after BoNT-A treatment, 85% and 90% of patients achieved the a priori definition of treatment responder. Patients reported less occupational and emotional impairment, spent less time managing their hyperhidrosis, and had fewer difficulties in social situations. Adverse events were uncommon (5.5%), were mild, and did not require treatment. At study end, 53% of patients reported no dermatology-specific HRQOL impairment and 90% were satisfied with treatment. CONCLUSIONS: Significant, meaningful, rapid, and durable reductions in disease severity and functional impairment, as well as improvements in HRQOL, were seen following BoNT-A treatment. BoNT-A was safe and well tolerated, producing high levels of patient satisfaction. 相似文献
75.
Jonathan D Schiff Michelle L Ramírez Natan Bar-Chama 《Endocrinology & Metabolism Clinics of North America》2007,36(2):313-331
Male infertility is the result of a variety of highly treatable conditions. The critical step in treating male infertility is to evaluate properly every male partner of an infertile couple and to generate the proper treatment strategy. There are many medical and surgical options that can help most couples overcome male factor infertility. Male infertility can most easily be broken down into problems of sperm production (testicular dysfunction) and problems of sperm transport (obstruction). When applicable, medical therapies are used as an initial strategy to improve sperm production or as a preliminary therapy to boost production transiently in anticipation of a surgical sperm retrieval attempt. A range of surgical options is available to correct varicoceles, reconstruct the obstructed system, or retrieve sperm for assisted reproduction. 相似文献
76.
77.
78.
79.